Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization

Inclusion Criteria: * Female patients 18-75 years of age inclusive * Stable angina classified as CCS III or IV * Receiving treatment with at least two classes of chronic anti-anginal medication, of which two are at the maximally tolerated dose * Left ventricular ejection fraction (LVEF) of ≥30% * Not a candidate for, or unlikely to benefit from standard revascularization procedures as verified by an independent cardiologist or cardiothoracic surgeon (not a study investigator) at each center * Can undergo ETT using the modified Bruce protocol and; 1. ECG changes diagnostic of myocardial ischemia occur during the first 10 minutes of exercise 2. Variability of the time to onset of ECG changes diagnostic of myocardial ischemia is ≤25% or within 60 seconds if the time to onset of myocardial ischemia occurs within the first 4 minutes of exercise as determined by two consecutive screening treadmill tests * Evidence of stress induced myocardial ischemia by adenosine SPECT, defined as a reversible perfusion defect size of ≥9% * Willing and able to comply with the study requirements including long-term follow-up * Provided written informed consent Exclusion Criteria: * Patients of childbearing potential (must be surgically sterile or post-menopausal) * Patients for whom an immediate revascularization procedure is indicated (CABG surgery or PCI) * Myocardial infarction within the past 3 months * Unstable angina or hospitalization requiring intravenous anti-anginal therapy within the 14 days prior to the start of screening evaluations * Congestive heart failure NYHA Class IV * Electrocardiogram that precludes accurate assessment of exercise induced myocardial ischemia (e.g., left bundle branch block, Wolf-Parkinson-White syndrome, atrial fibrillation) * Myocarditis or restrictive pericarditis * Left main coronary stenosis ≥70% (unless the patient has a patent graft or collateral vessels supplying the left coronary circulation) or proximal stenoses ≥70% in all major coronary conduit vessels (coronary arteries and bypass grafts) * Clinically significant aortic or mitral valvular heart disease * Coronary ostial stenosis that precludes adequate catheter engagement in any target vessel * Coronary artery to venous communications, which bypass the coronary capillary bed * Untreated life-threatening ventricular arrhythmias * CABG surgery within the past 6 months, unless those grafts are now occluded. * Percutaneous transluminal angioplasty (PTCA) within the past 3 months, unless the dilated vessel(s) are now occluded * Enhanced external counterpulsation (EECP) within 3 months prior to the start of screening evaluations * Transmyocardial or percutaneous myocardial laser revascularization within the previous year * Prior treatment with any cardiovascular gene or stem cell therapy. * Any intercurrent illness that may interfere with their ability to perform a maximal ETT * Any major organ disease that substantially impairs life expectancy. * History of cancer, other than basal cell carcinoma, or patients with any laboratory or physical exam or diagnostic procedure finding suggestive of current malignancy * Moderate to severe nonproliferative or proliferative retinopathy from any cause (ETDRS score \>35), clinically significant macular edema, or previous panretinal photocoagulation therapy * Heparin induced thrombocytopenia or history of idiopathic thrombocytopenic purpura or other medical condition causing thrombocytopenia * SGPT level greater than 2.0 times the upper limit of the laboratory normal range * Bilirubin level ≥2.0 mg/dL * Serum creatinine ≥2.5 mg/dL * Platelet count \<100,000/μL * White blood cell count \<3,000/μL * Positive test for hepatitis B or C * Positive test for HIV * History of colon cancer in a first degree relative (i.e., parent, sibling or offspring) unless the patient has undergone a colonoscopy in the past 36 months with negative findings * History of breast cancer in a first degree relative * Patient in a family with any documented hereditary cancer syndrome * Prior anaphylaxis reaction to iodinated contrast agents * Patients who are known to be immunosuppressed or are receiving chronic treatment with immunosuppressive drugs * Received an investigational drug or biologic within 30 days of screening or are currently participating in an investigational drug, biologic or device trial